Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 341-346

  Tremblay Mercier, Jennifer ^a   Tessier, Daniel ^a,b   Plourde, Mélanie ^a,c   Fortier, Mélanie ^a   Lorrain, Dominique ^a,b   Cunnane, Stephen C ^a,b  

^a UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BEZAFIBRATE; CARBON 13; FATTY ACID; GLUCOSE; INSULIN; KETONE; LINOLEIC ACID; TRIACYLGLYCEROL;

AGED; ARTICLE; CLINICAL ARTICLE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; KETOGENESIS; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77953730768     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166504     Document Type: Article

References (41)

1. Anderlová K, Dolezalová R, Housová J, Bosanská L, Haluzíková D, Kremen J, Skrha J, and Haluzík M (2007) Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res 56:579-586.
2. Asplund-Carlson A (1996) Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. J Cardiovasc Risk 3:385-390.
3. Blennow K, de Leon MJ, and Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403.
4. Carpentier AC (2008) Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. Diabetes Metab 34:97-107.
5. Chapman MJ (2003) Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171:1-13.
6. Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, and Wolfe RR (2007) Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment. Mech Ageing Dev 128:558-565.
7. Cullingford TE (2004) The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot Essent Fatty Acids 70:253-264.
8. Cullingford TE, Dolphin CT, and Sato H (2002) The peroxisome proliferator-activated receptor alpha-selective activator ciprofibrate upregulates expression of genes encoding fatty acid oxidation and ketogenesis enzymes in rat brain. Neuropharmacology 42:724-730.
9. Cunnane SC, Ryan MA, Nadeau CR, Bazinet RP, Musa-Veloso K, and McCloy U (2003) Why is carbon from some polyunsaturates extensively recycled into lipid synthesis? Lipids 38:477-484.
10. D'Costa MA and Angel A (1975) Inhibition of hormone-stimulated lipolysis by clofi-brate. A possible mechanism for its hypolipidemic action. J Clin Invest 55:138-148.
11. Damci T, Tatliagac S, Osar Z, and Ilkova H (2003) Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 14:357-360.
12. de Lorgeril M, Salen P, Guiraud A, Zeghichi S, Boucher F, and de Leiris J (2005) Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutr Metab Cardiovasc Dis 15:36-41.
13. Dufouil C, Richard F, Fiévet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, and Alpérovitch A (2005) APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64:1531-1538.
14. Edmond J, Robbins RA, Bergstrom JD, Cole RA, and de Vellis J (1987) Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J Neurosci Res 18:551-561.
15. Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509.
16. Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, and Di Chiro G (1984) Cortical abnormalities in Alzheimer's disease. Ann Neurol 16:649-654.
17. Freemantle E, Vandal M, Tremblay Mercier J, Plourde M, Poirier J, and Cunnane SC (2009) Metabolic response to a ketogenic breakfast in the healthy elderly. J Nutr Health Aging 13:293-298.
18. Fukao T, Lopaschuk GD, and Mitchell GA (2004) Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids 70:243-251.
19. Henderson ST (2008) Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 5:470-480.
20. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, and Costantini LC (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6:31.
21. Hoyer S (1996) Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol Scand Suppl 165:18-24. (Pubitemid 26143163)
22. Issemann I and Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650. (Pubitemid 120028995)
23. Jonkers IJ, de Man FH, van der Laarse A, Frölich M, Gevers Leuven JA, Kamper AM, Blauw GJ, and Smelt AH (2001) Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens 19:749-755.
24. Kim JI, Tsujino T, Fujioka Y, Saito K, and Yokoyama M (2003) Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 26:307-313.
25. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, and Gong CX (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 101:10804-10809.
26. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, and Gong CX (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582:359-364.
27. Mannaerts GP, Thomas J, Debeer LJ, McGarry JD, and Foster DW (1978) Hepatic fatty acid oxidation and ketogenesis after clofibrate treatment. Biochim Biophys Acta 529:201-211.
28. McGarry JD and Foster DW (1977) Hormonal control of ketogenesis. Biochemical considerations. Arch Intern Med 137:495-501.
29. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, and de Leon MJ (2007) Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 42:129-138.
30. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, and Cahill GF Jr (1967) Brain metabolism during fasting. J Clin Invest 46:1589-1595.
31. Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, and Sherwin RS (2009) Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes 58:1237-1244.
32. Petit-Taboué MC, Landeau B, Desson JF, Desgranges B, and Baron JC (1998) Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 7:176-184.
33. Plourde M, Tremblay-Mercier J, Fortier M, Pifferi F, and Cunnane SC (2009) Eicosapentaenoic acid decreases postprandial beta-hydroxybutyrate and free fatty acid responses in healthy young and elderly. Nutrition 25:289-294.
34. Rapoport SI, Chang MC, and Spector AA (2001) Delivery and turnover of plasmaderived essential PUFAs in mammalian brain. J Lipid Res 42:678-685.
35. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, and Craft S (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25:311-314.
36. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, and Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101:284-289.
37. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Järvinen H, and Taskinen MR (1995) Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 44:589-596.
38. Soeters MR, Sauerwein HP, Faas L, Smeenge M, Duran M, Wanders RJ, Ruiter AF, Ackermans MT, Fliers E, Houten SM, et al. (2009) Effects of insulin on ketogenesis following fasting in lean and obese men. Obesity (Silver Spring) 17:1326-1331.
39. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, et al. (2007) Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 194:265-271.
40. Wagner JA, Larson PJ, Weiss S, Miller JL, Doebber TW, Wu MS, Moller DE, and Gottesdiener KM (2005) Individual and combined effects of peroxisome proliferator- activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 45:504-513.
41. Yamamoto K, Fukuda N, Zhang L, and Sakai T (1996) Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate. Pharmacol Res 33:337-342.